Sentences with phrase «cell tumors often»

While canine mast cell tumors often appear small and insignificant, they can be a very serious form of cancer in dogs.

Not exact matches

A successful test would therefore require isolating enough of these scarce cells to make statistically valid inferences about the tumor, often at a stage when the tumor itself is growing and changing rapidly.

Tumors often shed cells and subcellular components into the bloodstream, but these are exceedingly hard to detect.

The diagnosis of cancer and study of disease progression is often accomplished by examining a tumor sample containing many billions or even trillions of cells.

Metastasis, the strategy adopted by tumor cells to transform into an aggressive form of cancer, are often associated with a gloomy prognosis.

In the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytes.

«Tumor cells often produce suppressive factors which essentially turn the brakes on tumor - killing white blood cTumor cells often produce suppressive factors which essentially turn the brakes on tumor - killing white blood ctumor - killing white blood cells.

One advantage of this method is that it only activates a certain type of immune cell, the dendritic cell or T - cell, and only in one part of the body, near the draining lymph nodes or tumor, which helps cut down on the system - wide side effects often seen with chemotherapy.

Pancreatic neuroendocrine tumors, often referred to as «islet cell tumors» are a type of cancer that arises from hormone - releasing cells in the pancreas.

«When cancer comes back, it's genetically very similar to the original tumor but often with additional mutations that may give cancer cells new strategies to survive attack by whatever drugs are thrown at them.

The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining cells adapt to treatment and become resistant.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

Among factors that might skew the results: failure of participants — especially those with tumors — to accurately recall exactly how long and often they talk on their cell phones.

Semenza says previous studies have shown that resistance to chemotherapy arises from the hardy nature of cancer stem cells, which are often found in the centers of tumors, where oxygen levels are quite low.

One miRNA can target multiple genes, but their expression is often hijacked by cancer cells and disrupts multiple cancer - causing or tumor - suppressing pathways,» says Shuk - Mei Ho, PhD, director of the CCC and Jacob G. Schmidlapp Chair of Environmental Health and professor at the University of Cincinnati (UC) College of Medicine.

If metastatic cancers are most often made up of cells with different genetic drivers, perhaps researchers should be targeting the primary tumor with multiple drugs to contain the cancer.

For the CRISPR trial, a UPenn - led team wants to remove T cells from patients and use a harmless virus to give the cells a receptor for NY - ESO - 1, a protein that is often present on certain tumors but not on most healthy cells.

When looking for culprits, researchers have often focused their microscopes on macrophages, which occupy a meaningful spot among the white blood cells in the tumor microenvironment.

Tumor cells associated with pancreatic cancer often behave like communities by working with each other to increase tumor spread and growth to different orTumor cells associated with pancreatic cancer often behave like communities by working with each other to increase tumor spread and growth to different ortumor spread and growth to different organs.

This pattern of adaptation is often seen in tumor cells, according to J. Alan Diehl, Ph.D., the SmartState Endowed Chair in Lipidomics, Pathobiology and Therapy at the MUSC Hollings Cancer Center and senior researcher on the project.

In addition, cancer cells» susceptibility to these agents varies widely, and tumors often develop resistance to drugs that initially seem effective.

PD - 1 is often aberrantly engaged by tumor cells themselves to thwart T cell attack.

Given that breast cancer cells traveling through the bloodstream on their way to secondary sites where breast tumors metastasize most often — lung, bone marrow, brain and liver — must first pass through the basement membrane microvasculature, Ghajar and Bissell suspected that the basement membrane could be a major component of the dormant niche in distant organs.

Bone marrow biopsies often produce limited numbers of tumor cells to test — as few as 50,000 tumor cells in this study — but for this technique that is enough to test many different drugs and drug combinations.

The human immune system is poised to spring into action at the first sign of a foreign invader, but it often fails to eliminate tumors that arise from the body's own cells.

Researchers studying the brain tumor type glioma often use a cell line called U87MG that was established at Uppsala University almost fifty years ago.

A cell line consists of cultured cells that often originate from a tumor.

These genetic differences have often been blamed when chemotherapy or other treatments have been unsuccessful, as it was believed that the therapy may not have targeted all of the cells within the tumor.

A good omen: These stem cells didn't create the tumors that transplanted embryonic stem cells often trigger.

Tumor cells often over express these checkpoint molecules, putting the brakes on the immune system's search and destroy work.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

This therapeutic approach uses the body's own T cells to attack tumors — but often the therapy is unreliable.

However, these therapies often fail because insufficient numbers of T cells reach the tumor.

Several anti-cancer drugs attempt to halt the growth of tumors by blocking mTOR, a key part of a growth - regulating network that is often disrupted in cancer cells.

This could help eliminate the residual cancer cells that often form new tumors following surgery.

Surgery, followed by radiation treatment, is usually recommended, but it is difficult to remove every last cancer cell and the tumor often rebounds.

The standard treatment kills the bulk of the tumor cells but often leaves the stem cells intact to regenerate the tumor.

Tumor cells often secrete chemicals that suppress the immune system, making it difficult for the body to attack tumors on its own.

Loss of this function causes tumor formation through uncontrolled stimulation of AKT, an enzyme that stimulates cell proliferation and survival and is often hyperactive in human tumors.

Tumor cells often bedeck themselves with sialyl - Lewisx molecules, and the rogue cells could be using them to escape detection by the immune system, he adds.

Such resistance may help explain why drugs that eradicate tumor cells in laboratory dishes often fail to eliminate malignancies in the body

It is also often mutated in other common B cell tumors, such as mantle cell lymphoma.

Bone marrow transplantation (hematopoetic stem cell transplantation) can also be considered immunotherapy because the donor's immune cells will often attack the tumor or cancer cells that are present in the host.

As tumors proliferate, they often outgrow their blood supply so that many cells die, sending more PS into circulation.

In the liver, tumor cells occupied the sinusoids and surrounded the central vein with a granulomatous pattern, often eroding the walls and invading the lumen (Fig. 2A) ⇓.

Interestingly tumor cells, whilst not allogeneic, are in many cases both «altered - self» and immunogenic but often actively modulate immune responsiveness to evade immune surveillance 76.

However, unfortunately the mechanisms of tumor cells have the ability to resist to immunotherapy and patients who relapse with acquired resistance to BRAF and MEK inhibitors often present with melanomas that display a much more aggressive and invasive phenotype [13, 14].

Often these mutations make the cancer cells resistant to normal programmed cell death, and the cells will divide over and over, forming a solid tumor.

Yoon says the presence of these cells could be a marker for tumor growth and metastasis. Because tumors often metastasize along lymph ducts and into lymph nodes, studying this type of cells could lead to new targets for blocking tumor metastasis.

Coukos, who is currently leading an ovarian cancer clinical trial sponsored by CRI's Clinical Accelerator, sought to understand why PD - 1 / PD - L1 immunotherapies are often ineffective for these patients, even though ovarian tumors are often infiltrated by «killer» T cells that recognize tumor - specific neoantigens and express high levels of PD - 1.